Pediatric acute liver failure of undetermined cause: A research workshop

Estella M Alonso1, Simon P Horslen2, Edward M Behrens3

  • 1Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.

Hepatology (Baltimore, Md.)
|November 19, 2016
PubMed

Insights

Pediatric acute liver failure (PALF) with unknown causes is linked to hyperinflammation, similar to HLH/MAS. Impaired T-cell function and suppressed progenitor cells hinder liver regeneration and recovery in children.

Area of Science:

  • Hepatology
  • Immunology
  • Pediatric Critical Care

Background:

  • Pediatric acute liver failure (PALF) is a severe condition in children with a significant percentage lacking a clear diagnosis.
  • Undetermined PALF cases exhibit poorer outcomes, including lower survival and higher transplant/death rates.
  • The clinical presentation of indeterminate PALF resembles hyperinflammatory conditions like hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS).

Purpose of the Study:

  • To integrate research findings on indeterminate PALF.
  • To establish a foundation for new mechanistic studies and future treatment trials.
  • To explore the role of inflammation and cellular dysfunction in PALF pathogenesis.

Main Methods:

  • Workshop convening clinicians and basic scientists.
  • Review of clinical phenotypes and inflammatory markers.
  • Discussion of cellular mechanisms in hepatic regeneration.

Main Results:

  • Indeterminate PALF shares features with HLH and MAS, suggesting a hyperinflammatory component.
  • Failure of cytotoxic T cells may impair inflammatory control, leading to liver injury.
  • Bone marrow-derived sinusoidal endothelial cell progenitor cells (sprocs) are crucial for hepatic regeneration but may be suppressed by inflammation.

Conclusions:

  • Insights from HLH/MAS trials may guide PALF therapeutic strategies.
  • Reducing systemic inflammation and neuroinflammation is key to improving survival.
  • Multicenter collaboration and biorepository management are essential for rare disease research.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
247
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
306
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
346
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
605
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
411